IRON
Disc MedicineยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IRON Profile
Disc Medicine,Inc.
A clinical stage precision medicine company that developing innovative treatments for genetically-defined age-related macular degeneration
Biological Technology
06/25/2020
08/12/2020
NASDAQ Stock Exchange
84
12-31
Common stock
321 Arsenal Street, Suite 101, Watertown, Massachusetts 02472
--
Disc Medicine, Inc., was incorporated in Delaware on June 25, 2020. The company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapies for patients with severe hematological disorders. The company has assembled a series of clinical and preclinical product candidates designed to modify fundamental biological pathways related to erythrocyte formation and function, specifically heme biosynthesis and iron homeostasis. The company's current pipeline includes bitopertin for the treatment of erythropoietic porphyria, or EP, including erythropoietic protoporphyria, or EPP, and X-linked protoporphyria, or XLP, As well as Diamond-BlackFan anemia or DBA; DISC-0974 for the treatment of myelofibrosis or MF anemia and chronic kidney disease anemia or CKD; and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia versatile, or PV, and diseases of the blood system. In addition, the company's preclinical programs include DISC-0998 for the treatment of anemia associated with inflammatory diseases. The company's approach to product candidate development utilizes well-understood molecular mechanisms that have been validated in humans. The company believes that each product candidate, if approved, has the potential to improve the lives of patients with hematological disorders.
